Evolva (EV-035 Series) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $29.7M

Evolva (EV-035 Series) General Information


Provider of antibiotics. The business unit is an anti-bacterial programme which includes broad-spectrum antibiotic GC-072, which is being developed with US government bio-defense funding.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • Reinach
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evolva (EV-035 Series) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Merger/Acquisition 17-Dec-2014 $29.7M 000.00 Completed Product Development
To view Evolva (EV-035 Series)’s complete valuation and funding history, request access »

Evolva (EV-035 Series) Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Evolva Corporation Majority 000 0000 000000 0
To view Evolva (EV-035 Series)’s complete investors history, request access »